Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan

References

• Shea JB, Sears SF. Cardiology patient pages. A patient’s guide to living with atrial fibrillation. Circulation 2008;117:e340-e343
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl3):429S-456S
   Web of Science ®Google Scholar
• Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2014;11:639-54
   PubMed Web of Science ®Google Scholar
• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142-7
   PubMed Web of Science ®Google Scholar
• Harburger JM, Aronow WS. Newer anticoagulants for non-valvular atrial fibrillation. Pharmaceuticals (Basel) 2012;5:469-80
   PubMedGoogle Scholar
• Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:2254
   Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-104
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008;6:1500-6
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010;3:624-31
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104
   PubMed Web of Science ®Google Scholar
• Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011;31:326-43
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 2016;5:e003725
   PubMed Web of Science ®Google Scholar
• Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thromb Haemost 2016;116:975-86
   PubMed Web of Science ®Google Scholar
• Chang HY, Zhou M, Tang W, et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350:h1585
   PubMed Web of Science ®Google Scholar
• Maura G, Blotière PO, Bouillon K, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 2015;132:1252-60
   PubMed Web of Science ®Google Scholar
• Hernandez I, Baik SH, Piñera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015;175:18-24
   PubMed Web of Science ®Google Scholar
• Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857
   PubMed Web of Science ®Google Scholar
• Adeboyeje G, Sylwestrzak G, White J, et al. Comparative effectiveness and safety of anticoagulant therapy with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. Circ Cardiovasc Qual Outcomes 2016;9(Suppl2):A2
   Google Scholar
• Deitelzweig S, Bruno A, Trocio J, et al. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Curr Med Res Opin 2016;32:573-82
   PubMed Web of Science ®Google Scholar
• Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest 2016;150:1302-12
   PubMed Web of Science ®Google Scholar
• Xie L, Vo L, Keshishian A, et al. Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: an early view. J Med Econ 2016;19:769-76
   PubMed Web of Science ®Google Scholar
• Farr AM, Jing Y, Johnston S, et al. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin. Hosp Pract 2015;43:172-9
   Google Scholar
• Amin A, Bruno A, Trocio J, et al. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. J Med Econ 2015;18:399-409
   PubMed Web of Science ®Google Scholar
• Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther 2014;8:789-98
   PubMed Web of Science ®Google Scholar
• Optum [Internet]. Eden Prairie, MN: Optum; c2017. Clinformatics Data Mart; 2014. Available at: https://www.optum.com/content/dam/optum/resources/productSheets/Clinformatics_for_Data_Mart.pdf
   Google Scholar
• Willke RJ, Mullins CD. “Ten commandments” for conducting comparative effectiveness research using “real-world data”. J Manag Care Pharm 2001;17(SupplA9):S10-S15
   Google Scholar
• Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I. Value Health 2009;12:1044-52
   PubMed Web of Science ®Google Scholar
• Cox E, Martin BC, Van Staa T, et al. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II. Value Health 2009;12:1053-61
   PubMed Web of Science ®Google Scholar
• Johnson ML, Crown W, Martin BC, et al. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III. Value Health 2009;12:1062-73
   PubMed Web of Science ®Google Scholar
• Jensen PN, Johnson K, Floyd J, et al. Identifying atrial fibrillation from electronic medical data: a systematic review. Pharmacoepidemiol Drug Saf 2012;21:141-7
   PubMed Web of Science ®Google Scholar
• Teutsch C, Huisman MV, Lip GY, et al. Persistence with dabigatran therapy for stroke prevention in patients with non-valvular atrial fibrillation: the Gloria-AF Registry. Blood 2016;128:2616
   PubMed Web of Science ®Google Scholar
• Thigpen JL, Dillon C, Forster KB, et al. Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes 2015;8:8-14
   PubMed Web of Science ®Google Scholar
• Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 2011;20:560-6
   PubMed Web of Science ®Google Scholar
• Crawford M, Church J, Akin B. CPI detailed report data for December 2015. Washington, D.C.: Bureau of Labor Statistics. 2015. Available at: https://www.bls.gov/cpi/cpi_dr.htm
   Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GYH, et al.; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
   PubMed Web of Science ®Google Scholar
• Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014;33:1242-58
   PubMed Web of Science ®Google Scholar
• King G, Nielson R. Why propensity scores should not be used for matching. Cambridge, Harvard University. 2016. Available at: https://gking.harvard.edu/files/gking/files/psnot.pdf
   Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-107
   PubMed Web of Science ®Google Scholar
• Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. Health Serv Outcomes Res Method 2000;1:185-202
   Google Scholar
• Lachenbruch PA. Comparisons of two-part models with competitors. Stat Med 2001;20:1215-34
   PubMed Web of Science ®Google Scholar
• Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:2141-7
   PubMed Web of Science ®Google Scholar
• Li XS, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost 2017;117:1072-82
   PubMed Web of Science ®Google Scholar
• Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health 2013;16:498-506
   PubMed Web of Science ®Google Scholar
• Canestaro WJ, Patrick AR, Avorn J, et al. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes 2013;6:724-31.
   PubMed Web of Science ®Google Scholar
• Kamel H, Easton JD, Johnston SC, et al. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology 2012;79:1428-34
   PubMed Web of Science ®Google Scholar
• Amin A, Stokes M, Wu N, et al. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation. J Med Econ 2013;16:1193-202
   PubMedGoogle Scholar
• Vaughan Sarrazin MS, Jones M, Mazur A, et al. Cost of hospital admissions in Medicare patients atrial fibrillation taking warfarin, dabigatran, or rivaroxaban. J Am Coll Cariodol 2017;69:360-2
   PubMed Web of Science ®Google Scholar